Trials / Recruiting
RecruitingNCT06961669
Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma
An Early Exploratory Clinical Study of Enhanced Autologous CAR-T Cell Injection (ECAR01) Targeting CD19 and BCMA in Patients With Relapsed or Refractory Multiple Myeloma, Acute B-Cell Leukemia, and B-Cell Lymphoma
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Anhui Provincial Hospital · Other Government
- Sex
- All
- Age
- 3 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with Relapsed or Refractory Multiple Myeloma, Acute B-Cell Leukemia, and B-Cell Lymphoma. This study aims to evaluate the safety and efficacy of the treatment with Anti-BCMA and CD19 CART
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anti-BCMA and CD19 CART cells will be injected intravenously on a one-time basis | A single intravenous infusion of anti-BCMA and CD19 CART cells (dose-escalating infusion of 1.0-5.0 x10\^5 CART cells/kg）. |
Timeline
- Start date
- 2025-04-16
- Primary completion
- 2028-08-31
- Completion
- 2028-08-31
- First posted
- 2025-05-08
- Last updated
- 2025-05-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06961669. Inclusion in this directory is not an endorsement.